(3,5-二氯苄基)-肼 | 51421-25-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3,5-二氯苄基)-肼
• 英文名称: 3,5-dichlorobenzylhydrazine
• 英文别名: (3,5-Dichlorobenzyl)hydrazine；(3,5-dichlorophenyl)methylhydrazine
• CAS: 51421-25-1
• 化学式: C₇H₈Cl₂N₂
• 分子量: 191.06
• InChiKey: DLPOEUZVERZKMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  (3,5-二氯苄基)-肼 在 亚硝酸丁酯 、 sodium ethanolate 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 16.0h， 生成 sodium (E)-(3,5-dichlorophenyl)methanediazoate
  参考文献：
  名称：

  Mechanisms of Benzyl Group Transfer in the Decay of (E)-Arylmethanediazoates and Aryldiazomethanes in Aqueous Solutions

  摘要：

  Rate constants are reported for the buffer-independent decay of ten (E)-arylmethanediazontes in aqueous media at 25 degrees C, ionic strength 1 M (NaClO4), 4% 2-propanol, in the region of pH 4-12. The rate constants are proportional to hydrogen ion concentration at high pH and become pH independent in the low-pH region. Varying concentrations of oxyanion, amine, and hydrazine buffers over the range 0.05-0.2 M increased the pseudo-first-order rate constant for decay of the diazoates by less than 10%. The azide-water selectivities, k(2)/k(5), for partitioning of the benzyl groups in the decay of (E)-(3,5-bis(trifluoromethyl)phenyl)methanediazonate and the (3,5-bis(trifluoromethyl)phenyl)diazomethane are determined to be 0.20 and 0.21 M(-1), respectively, in phosphate buffered water and 0.27 and 0.26 M(-1), respectively, in 20/80 DMSO-water. It is concluded that these two reactants decompose, in these media, via a common free diazonium ion intermediate that is formed in the case of the diazoate upon unassisted N-O bond cleavage of the diazoic acid. A common rate-limiting step is indicated for all the diazoates by the correlation line for the plot of log k(1), the pH independent rate constant, against sigma that has a slope rho = -1.23. Product ratios for trapping of benzyl groups derived from other pairs of arylmethanediazoates and aryldiazomethanes with less electron withdrawing groups are different outside experimental error, indicating the importance of different nitrogen-separated ion pairs in these reactions. The (E)-(p-methoxy)phenyl)methane-(16)-diazoat decomposes in O-16/O-18 water to give alcohol that has an ''excess'' abundance of O-16 compared to solvent, Decomposition of the same compound in 50/50 trifluoroethanol-water with varying concentrations of azide indicates that azide ion appears to trap a limiting amount, similar to 80%, of the p-methoxybenzyl group. Quantitative analysis of the data indicates that 16% of the p-methoxybenzyl cation is trapped by solvent at the nitrogen-separated ion pair stage, in the absence of azide ion, There is a 9-fold enhancement of selectivity for trifluoroethanol at the ion pair stage that is ascribed to a proton switch initiated by the leaving hydroxide ion in the ion pair. The values of k(2)/k(5) similar to 0.2 M(-1) and k(T)/k(H) similar to 0.5-0.6 for the trifluoroethanol-water selectivity and k(ET)/k(T) similar to 1 for the ethanol-trifluoroethanol selectivity are independent of substituent in the decay of arylmethanediazoates (X = H and EWG) in water, water-trifluoroethanol (50/50), and water-trifluoroethanol-ethanol (50/40/10), respectively. It is concluded from this that the product-determining steps do not involve chemical bonding but rather rotational/translational reorientation of the nucleophiles in the first solvation sphere of the carbocation intermediates. It is concluded that the values of k(H)/k(T) = 0.5-0.6 indicate preferential solvation of the cation precursor by trifluoroethanol. It is shown that a preferential interaction for trifluoroethanol of <1 kcal/mol is required to generate the observed selectivities.

  DOI：

  10.1021/ja00120a004
• 作为产物：
  描述：

  1,3-二氯-5-氯甲基苯 在 肼 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以56%的产率得到(3,5-二氯苄基)-肼
  参考文献：
  名称：

  Mechanisms of Benzyl Group Transfer in the Decay of (E)-Arylmethanediazoates and Aryldiazomethanes in Aqueous Solutions

  摘要：

  Rate constants are reported for the buffer-independent decay of ten (E)-arylmethanediazontes in aqueous media at 25 degrees C, ionic strength 1 M (NaClO4), 4% 2-propanol, in the region of pH 4-12. The rate constants are proportional to hydrogen ion concentration at high pH and become pH independent in the low-pH region. Varying concentrations of oxyanion, amine, and hydrazine buffers over the range 0.05-0.2 M increased the pseudo-first-order rate constant for decay of the diazoates by less than 10%. The azide-water selectivities, k(2)/k(5), for partitioning of the benzyl groups in the decay of (E)-(3,5-bis(trifluoromethyl)phenyl)methanediazonate and the (3,5-bis(trifluoromethyl)phenyl)diazomethane are determined to be 0.20 and 0.21 M(-1), respectively, in phosphate buffered water and 0.27 and 0.26 M(-1), respectively, in 20/80 DMSO-water. It is concluded that these two reactants decompose, in these media, via a common free diazonium ion intermediate that is formed in the case of the diazoate upon unassisted N-O bond cleavage of the diazoic acid. A common rate-limiting step is indicated for all the diazoates by the correlation line for the plot of log k(1), the pH independent rate constant, against sigma that has a slope rho = -1.23. Product ratios for trapping of benzyl groups derived from other pairs of arylmethanediazoates and aryldiazomethanes with less electron withdrawing groups are different outside experimental error, indicating the importance of different nitrogen-separated ion pairs in these reactions. The (E)-(p-methoxy)phenyl)methane-(16)-diazoat decomposes in O-16/O-18 water to give alcohol that has an ''excess'' abundance of O-16 compared to solvent, Decomposition of the same compound in 50/50 trifluoroethanol-water with varying concentrations of azide indicates that azide ion appears to trap a limiting amount, similar to 80%, of the p-methoxybenzyl group. Quantitative analysis of the data indicates that 16% of the p-methoxybenzyl cation is trapped by solvent at the nitrogen-separated ion pair stage, in the absence of azide ion, There is a 9-fold enhancement of selectivity for trifluoroethanol at the ion pair stage that is ascribed to a proton switch initiated by the leaving hydroxide ion in the ion pair. The values of k(2)/k(5) similar to 0.2 M(-1) and k(T)/k(H) similar to 0.5-0.6 for the trifluoroethanol-water selectivity and k(ET)/k(T) similar to 1 for the ethanol-trifluoroethanol selectivity are independent of substituent in the decay of arylmethanediazoates (X = H and EWG) in water, water-trifluoroethanol (50/50), and water-trifluoroethanol-ethanol (50/40/10), respectively. It is concluded from this that the product-determining steps do not involve chemical bonding but rather rotational/translational reorientation of the nucleophiles in the first solvation sphere of the carbocation intermediates. It is concluded that the values of k(H)/k(T) = 0.5-0.6 indicate preferential solvation of the cation precursor by trifluoroethanol. It is shown that a preferential interaction for trifluoroethanol of <1 kcal/mol is required to generate the observed selectivities.

  DOI：

  10.1021/ja00120a004

文献信息

• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
  申请人：NOVIRA THERAPEUTICS INC

  公开号：WO2013096744A1

  公开（公告）日：2013-06-27

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

  本发明包括一种抑制、压制或预防需要的人体内HBV感染的方法，包括向个体投给治疗有效量的至少一种本发明的化合物。
• ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：Clasby Martin C.

  公开号：US20080255156A1

  公开（公告）日：2008-10-16

  Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein: X 1 and X 2 are 1-3 substituents independently selected from the group consisting of H, alkyl, halo, —CF 3 , —OCF 3 , alkoxy, —OH and —CN; n is 0, 1 or 2; and R and R 1 are H or alkyl; also disclosed is the use of the compounds in the treatment of CNS diseases such as Parkinson's disease, alone or in combination with other agents for treating CNS diseases, pharmaceutical compositions comprising them and kits comprising the components of the combinations.

  具有结构式I或其药用可接受盐的化合物，其中：X1和X2分别选自H、烷基、卤、—CF3、—OCF3、烷氧基、—OH和—CN组成的1-3个取代基；n为0、1或2；R和R1为H或烷基；还公开了该化合物在治疗中枢神经系统疾病如帕金森病中的用途，单独或与其他治疗中枢神经系统疾病的药剂联合使用，包括它们的药物组合物和包含该组合物成分的工具包。
• 1-Substituted-3-amino-pyrazol-5-ones
  申请人：Bayer Aktiengesellschaft

  公开号：US03950528A1

  公开（公告）日：1976-04-13

  Pharmaceutical compositions are prepared which comprise a diuretically effective amount, a saluretically effect amount or an antihypertensive amount of a compound of the formula ##SPC1## Or a pharmaceutically acceptable non-toxic salt thereof, wherein R is aryl which is either unsubstituted or substituted by A. 1, 2 or 3 identical or different substituents selected from the group consisting of halogen, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, alkenoxy of 2 to 6 carbon atoms, cycloalkyl of 5 to 7 carbon atoms, trifluoromethyl, trifluoromethoxy and phenyl; B. 1 or 2 identical or different substituents selected from the group consisting of nitro, cyano, lower alkylamino of 1 to 4 carbon atoms, a carbonamido moiety of the formula ##EQU1## and a sulphonamido moiety of the formula ##EQU2## wherein R.sub.1 and R.sub.2 are each hydrogen or straight or branched chain alkyl of 1 to 4 carbon atoms, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached are linked together to form a 5-, 6- or 7-membered heterocyclic ring wherein the nitrogen atom is the only heteroatom or wherein oxygen is also present as a ring member; C. one substituent selected from the group consisting of dialkylamino of 1 to 4 carbon atoms in each alkyl moiety, nitro, cyano and SO.sub.n -alkyl of 1 to 4 carbon atoms, wherein n is 0, 1 or 2; D. one substituent selected from the group consisting of a moiety of the formula ##EQU3## wherein R.sub.1 and R.sub.2 are as above defined, nitro, cyano, a carbonamido moiety of the formula ##EQU4## wherein R.sub.1 and R.sub.2 are as above defined, a sulphonamide moiety of the formula ##EQU5## wherein R.sub.1 and R.sub.2 are as above defined, and SO.sub.n -alkyl of 1 to 4 carbon atoms, wherein n is 0, 1 or 2, and 1 or 2 substituents selected from the group consisting of alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 6 carbon atoms, halogen and trifluoromethyl; E. an annellated-branched or unbranched, saturated or unsaturated, 5-, 6- or 7-membered isocyclic or heterocyclic ring having 1 or more heteroatoms selected from the group consisting of oxygen and sulphur and wherein said aryl moiety is either unsubstituted or chlorosubstituted; F. --O--(CH.sub.2).sub.n.sub.' --N(alkyl).sub.2, wherein the alkyl groups contain a total of 2 to 4 carbon atoms and n'is 2 or 3; or G. two different substituents selected from the group consisting of alkyl of 1 to 8 carbon atoms, phenyl, halogen, alkoxy of 1 to 8 carbon atoms, trifluoromethyl, trifluoromethoxy, lower alkylamino, nitro, cyano, SO.sub.n --alkyl of 1 to 4 carbon atoms, wherein n is 0, 1 or 2, a carbonamido moiety of the formula ##EQU6## and a sulphonamido moiety of the formula ##EQU7## wherein R.sub.3 and R.sub.4 are each hydrogen or alkyl of 1 to 4 carbon atoms; in combination with a pharmaceutically acceptable non-toxic inert diluent or carrier. Diuretic therapy, saluretic therapy and antihypertensive therapy is effected in humans and animals by administering an effective amount of the active ingredient as above defined.

  制备了药物组合物，其中包括一种利尿有效量、排盐有效量或抗高血压有效量的化合物，其化学结构如下：其中R是芳基，可以是未取代或由A取代的芳基，A是1、2或3个相同或不同的取代基，包括卤素、1至8个碳原子的烷基、1至8个碳原子的烷氧基、2至6个碳原子的烯氧基、5至7个碳原子的环烷基、三氟甲基、三氟甲氧基和苯基；B是1个或2个相同或不同的取代基，包括硝基、氰基、1至4个碳原子的较低烷基氨基、具有以下结构的羰基基团和具有以下结构的磺胺基团；C是来自以下群体的1个取代基，包括每个烷基基团中1至4个碳原子的二烷基氨基、硝基、氰基和1至4个碳原子的SO.sub.n-烷基，其中n为0、1或2；D是来自以下群体的1个取代基，包括具有以下结构的基团，其中R.sub.1和R.sub.2如上定义，硝基、氰基、具有以下结构的羰基基团，其中R.sub.1和R.sub.2如上定义，具有以下结构的磺胺基团，其中R.sub.1和R.sub.2如上定义，以及1至4个碳原子的SO.sub.n-烷基，其中n为0、1或2，以及来自以下群体的1个或2个取代基，包括1至8个碳原子的烷基、1至6个碳原子的烷氧基、卤素和三氟甲基；E是一个具有1个或多个氧和硫异原子的芳基取代或氯取代的芳基，其中芳基可以是环状分支或非分支、饱和或不饱和、5、6或7个成员的异环或杂环，F是--O--(CH.sub.2).sub.n' --N(烷基).sub.2，其中烷基基团总共含有2至4个碳原子，n'为2或3；或G是来自以下群体的两个不同的取代基，包括1至8个碳原子的烷基、苯基、卤素、1至8个碳原子的烷氧基、三氟甲基、三氟甲氧基、较低烷基氨基、硝基、氰基、1至4个碳原子的SO.sub.n-烷基，其中n为0、1或2，具有以下结构的羰基基团和具有以下结构的磺胺基团，其中R.sub.3和R.sub.4分别是氢或1至4个碳原子的烷基；与药学上可接受的无毒惰性稀释剂或载体结合。通常通过给人类和动物使用上述定义的活性成分的有效量来进行利尿疗法、排盐疗法和抗高血压疗法。
• US3950528A
  申请人：——

  公开号：US3950528A

  公开（公告）日：1976-04-13
• US4061653A
  申请人：——

  公开号：US4061653A

  公开（公告）日：1977-12-06